{"id":112,"date":"2026-08-20T23:45:51","date_gmt":"2026-08-20T23:45:51","guid":{"rendered":"https:\/\/astinovabiolabs.com\/blog\/?p=112"},"modified":"2026-08-20T23:45:51","modified_gmt":"2026-08-20T23:45:51","slug":"synthesis-of-gepotidacin-blujepa-drug-intelligence-dossier","status":"publish","type":"post","link":"https:\/\/astinovabiolabs.com\/blog\/synthesis-of-gepotidacin-blujepa-drug-intelligence-dossier\/","title":{"rendered":"synthesis of Gepotidacin (BLUJEPA) \u2014 Drug Intelligence Dossier"},"content":{"rendered":"\n

Compiled:<\/strong>\u00a02026-08-14 \u00b7\u00a0Trigger event:<\/strong>\u00a0FDA approval, 2025-03-25\u00a0Innovator:<\/strong>\u00a0GlaxoSmithKline LLC (US NDA holder; composition-of-matter patents held by Glaxo Group Limited). Developed with US government biodefense co-funding (BARDA OTA HHSO100201300011C; DoD\/DTRA HDTRA1-07-9-0002).\u00a0Status:<\/strong>\u00a0Approved NME<\/p>\n\n\n\n

Mechanism:<\/strong>\u00a0Gepotidacin is a first-in-class, bactericidal TRIAZAACENAPHTHYLENE antibacterial that inhibits bacterial DNA replication by inhibiting two bacterial type II topoisomerase enzymes \u2014 DNA gyrase (GyrA\/GyrB) and topoisomerase IV (ParC\/ParE) \u2014 which catalyse the ATP-dependent breakage, strand passage and religation of double-stranded DNA needed to relieve topological strain during replication. Unlike fluoroquinolones, which stabilise the enzyme\u2013DNA covalent cleavage complex at two metal-bridged sites and trap double-strand breaks, gepotidacin binds at a DISTINCT, NOVEL site and blocks the enzyme by a different mode: a single gepotidacin molecule engages the enzyme, interacting directly with the conserved catalytic aspartate of one GyrA\/ParC subunit (Asp82 in the studied enzyme; equivalent to GyrA Asp90 \/ ParC Asp86 in Neisseria gonorrhoeae) and indirectly, via a bridging water, with the aspartate of the second subunit. For most target pathogens gepotidacin provides WELL-BALANCED DUAL inhibition of both enzymes with comparable potency; because it inhibits two independent targets through the same novel interaction, high-level target-mediated resistance generally requires CONCURRENT mutations in BOTH enzymes (two distinct mutational events), conferring a low propensity for resistance and retained activity against many fluoroquinolone-resistant strains (whose mutations map to the quinolone-binding, not the gepotidacin-binding, positions). This is not absolute \u2014 reduced susceptibility has been seen in FQ-resistant N. gonorrhoeae when a pre-existing ParC D86N is joined by a new GyrA A92T mutation.<\/p>\n\n\n\n

Synthesis Route of the Originator<\/strong><\/p>\n\n\n\n

Gepotidacin is assembled CONVERGENTLY from three fragments: (LEFT) a racemic triazaacenaphthylene-dione core with a pendant CH2-mesylate, built over ~8 steps from 2-chloro-6-methoxy-3-nitropyridine + serinol (SNAr \u2192 acetonide protection \u2192 nitro reduction \u2192 N-alkylation with ethyl bromoacetate \u2192 lactam ring closure \u2192 oxidation \u2192 acetal cleavage \u2192 cyclodehydrative bis-mesylation); (CENTRE) tert-butyl piperidin-4-ylcarbamate (Boc-4-aminopiperidine, CAS 73874-95-0); (RIGHT) 3,4-dihydro-2H-pyrano[2,3-c]pyridine-6-carbaldehyde (CAS 527681-61-4). Endgame: N-ALKYLATION of the piperidine N onto the tricyclic mesylate (C\u2013N bond #1) \u2192 Boc removal \u2192 CHIRAL RESOLUTION to set the single (3R) centre (the core forms racemic from symmetric serinol; NO asymmetric step or chiral pool) \u2192 REDUCTIVE AMINATION (NaBH(OAc)3) of the (3R)-4-aminopiperidine with the pyranopyridine aldehyde (C\u2013N bond #2, final) \u2192 gepotidacin free base \u2192 mesylate (dihydrate, Form 1) drug substance. Only ONE of the two C\u2013N bonds is a reductive amination. Source: GSK patent estate (WO 2008\/128942 = US 8,389,524, gepotidacin mono-HCl = Example 39; pyranopyridine process US 8,759,523; crystalline-form WO 2021\/219637). No public OPRD\/J.Med.Chem. full-route paper exists; step conditions are patent-example values.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

a<\/sup>Reagents and conditions: (1) tert-butyl piperidin-4-ylcarbamate (Boc-4-aminopiperidine, ~1.0\u20131.2 eq), acetonitrile, pyridine (or other tertiary-amine base), 50\u201390 \u00b0C, ~5 h. The secondary piperidine nitrogen displaces the primary CH2-OMs on the tricyclic core. The core is racemic at this point (it derives from symmetric serinol). Conditions are patent-example values (WO2008\/128942 family) \u2014 verify before scale-up.; (2) HCl (4 M in 1,4-dioxane, or HCl\/CH2Cl2), ~20 \u00b0C, ~1 h; free-base on workup. Removes the tert-butyl carbamate to unmask the 4-amino group for the final reductive amination.; (3) Resolution of the racemate to the (3R) enantiomer \u2014 e.g. preparative chiral chromatography \/ SFC, or a diastereomeric-salt resolution (resolving agent\/method not publicly verified). The (3R) enantiomer is carried forward. The core is racemic because it is built from symmetric serinol (2-amino-1,3-propanediol); there is no asymmetric catalytic or chiral-pool step \u2014 the stereocentre is set here by separation.; (4) 3,4-dihydro-2H-pyrano[2,3-c]pyridine-6-carbaldehyde (1.0\u20131.1 eq), NaBH(OAc)3 (or NaBH3CN), Et3N, CHCl3\/MeOH (~9:1), rt, ~2 h; workup sat. NaHCO3, extract 20% MeOH\/CH2Cl2 (~32% for this stage in the patent example). Forms the secondary amine linking the pyranopyridine to the piperidine, giving gepotidacin free base (m\/z 448 [M+H]+). DRUG SUBSTANCE: free base + ~1 eq methanesulfonic acid, acetone, 50 \u00b0C then cool \u2192 gepotidacin MESYLATE dihydrate (Form 1; WO2021\/219637 A1); 750 mg base = 910.7 mg mesylate per tablet..<\/p>\n\n\n\n

Key intermediates<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Crystal Forms, Salts, and Solid-State Profile<\/h2>\n\n\n\n